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Background: The intravenous inodilator levosimendan was developed for the treatment of patients with acutely
decompensated heart failure. In the last decade scientiﬁc and clinical interest has arisen for its repetitive or
intermittent use in patients with advanced chronic, but not necessarily acutely decompensated, heart failure. Re-
cent studies have suggested long-lasting favourable effects of levosimendan when administered repetitively, in
terms of haemodynamic parameters, neurohormonal and inﬂammatory markers, and clinical outcomes. The
existing data, however, requires further exploration to allow for deﬁnitive conclusions on the safety and clinical
efﬁcacy of repetitive use of levosimendan.
Methods and results: A panel of 30 experts from 15 countries convened to review and discuss the existing data,
and agreed on the patient groups that can be considered to potentially beneﬁt from intermittent treatment
with levosimendan. The panel gave recommendations regarding patient dosing and monitoring, derived from
the available evidence and from clinical experience.ter, University of Helsinki Central Hospital, Helsinki, Finland. Tel.: +358 400443076.
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361M.S. Nieminen et al. / International Journal of Cardiology 174 (2014) 360–367Conclusions: The current data suggest that in selected patients and support out-of-hospital care, intermittent/re-
petitive levosimendan can be used in advanced heart failure to maintain patient stability. Further studies are
needed to focus on morbidity and mortality outcomes, dosing intervals, and patient monitoring. Recommenda-
tions for the design of further clinical studies are made.© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-SA license
(http://creativecommons.org/licenses/by-nc-sa/3.0/).1. Introduction
Advanced heart failure (HF) is characterised by repeated episodes of
cardiac decompensation, frequent and prolonged hospitalisation, and
severely compromised patient quality of life [1]. The ageing of the
population and the availability of improved life-prolonging treatment op-
tions are contributing to an increase in the burden of chronic advancedHF
[2]. The rising prevalence of this end-stage HF is not only associated with
substantial morbidity and mortality, but also causes signiﬁcant health-
care expenditure due mostly to repeated hospitalisations [3,4]. At each
successive admission for exacerbation of HF, the patient leaves the hospi-
tal with a more pronounced decrease in cardiac function and a higher
probability of further rehospitalisation at shorter intervals, as well as of
death [5].
In the past, some studies have suggested that continuous or inter-
mittent infusion of parenteral dobutamine or milrinone as inotropic
support could provide favourable effects to support the circulation and
heart function in long-term therapy of end-stage HF [6–12]. Such con-
tinuous or intermittent use of these traditional inotropic drugs has
remained, however, sporadic due to the evidence of increased risk of
mortality [13]. In this regard, two focused meta-analyses by Tacon
et al. [14] and by Nony et al. [15] were published which investigate
the use of dobutamine and phosphodiestherase inhibitors, respectively,
both failing to show any beneﬁt by those drugs.
In the early 2000s, a new drug became available for the treatment of
acutely decompensated HF, the inodilator levosimendan [16–18]. The
clinical data for levosimendan, which combines positive inotropic,
vasodilatory, and cardioprotective effects but does not evoke signiﬁcant
changes in oxygen requirements, were recently reviewed [19]. In the
last ﬁve years, there have been ten meta-analyses on the clinical data
of levosimendan from independent research groups [20–29], all of
which suggest a possible advantage of levosimendan in various
clinical settings.
In the last three editions of the European Society of Cardiology (ESC)
guidelines for the treatment of HF levosimendanwas included in the ar-
mamentarium of drugs that are available for the treatment of acute HF
[1,30,31]. In the recent literature and in clinical practice, there has been
interest in the use of i.v. levosimendan in chronic advanced HF, also for
planned repetitive use to potentially avoid acute decompensation and
frequent rehospitalisation and possibly improve other outcomes.
A panel of 30 experts from 15 countries (Austria, Czech Republic,
Finland, Germany, Greece, Hungary, Israel, Italy, Norway, Portugal,
Russia, Slovenia, Spain, Sweden, and Ukraine) convened in Munich on
17 October, 2013 to: (a) review the existing literature on planned
intermittent treatmentwith levosimendan for patients with chronic ad-
vanced HF; (b) agree on the patient groups that can be considered to
beneﬁtmost from this treatment; (c) outline preliminary recommenda-
tions for the use of planned intermittent treatment with levosimendan
for themanagement of these patients; and (d) suggest further studies or
meta-analyses. This consensus paper presents the conclusions of this
expert panel.
2. Pharmacokinetic and pharmacodynamic effects of levosimendan
Levosimendan provides both rapid and sustained effects, with the
rapid effects mediated by the parent drug, levosimendan, and the
sustained effects mediated by its active metabolite OR-1896 [32]. While
the half-life of levosimendan is 1.3 h, the plasma concentration of OR-1896 reaches its peak 2–3 days after levosimendan infusion. As
the effects of OR-1896 closely resemble those of levosimendan [33,34],
the parent-drug-related effects are carried forward. Pronounced
haemodynamic effects are seen within 1 h of bolus administration of
levosimendan (usually 6–12 μg/kg over 10 min). However, this use of
bolus administration can induce untoward effects, such as hypotension
and tachycardia, and should thus only be used if an immediate response
is required, and if the patient risk/beneﬁt ratio is judged to be favourable
[35].
After a 24-h infusion of levosimendan, its pharmacodynamic effects
(i.e., on cardiac output and pulmonary capillarywedge pressure) persist
for at least a week [36]. In the REVIVE II trial, which compared
levosimendan (bolus of 6–12 μg/kg over 10 min followed by 0.1–
0.2 μg/kg/min for 24 h) with placebo, on top of standard of care, in pa-
tients with acutely decompensated HF, the percentage of patients free
of dyspnoea favoured levosimendan over placebo, for up to 5 days
after the completion of treatment [37].
Pharmacokinetic data pertaining to 6-h infusions of levosimendan are
limited. In patients with pulmonary hypertension, assessment of their
pulmonary vascular resistance showed that a 6-h infusion is not sufﬁcient
to maintain the clinical effects of levosimendan for 2 weeks [38].
In man, the formation of the levosimendan metabolite OR-1896
depends on the acetylation status of the patient, whereby rapid
acetylators produce higher quantities of OR-1896 [39]. Contrary to
the assumption that rapid acetylators should experience more pro-
nounced haemodynamic effects after levosimendan infusion, the
efﬁcacy of levosimendan appears not to be affected by the patient
acetylation status [40].
3. Long-term effects of levosimendan on cytokines
and neurohormones
Heart failure is a systemic condition in which neurohormonal and
inﬂammatory activation mediates cardiac remodelling and clinical
progression [41]. Sustained neurohormonal and anti-inﬂammatory
effects of levosimendan have been shown in patients with advanced
HF. In patients with reduced left ventricular ejection fraction (LVEF),
levosimendan can reduce the brain natriuretic peptide (BNP) levels,
which parallels the improvement in systolic and diastolic functions
[42]. These BNP-lowering effects of levosimendan are signiﬁcantly
more pronounced and prolonged than those of dobutamine [43].
According to two studies, levosimendan induces reductions in TNF-
α and IL-6 levels [44,45], which is not the case for dobutamine or place-
bo [44]. Moreover, proapoptotic factors like sFas and Fas-ligand are sig-
niﬁcantly reduced for extended periods of time [44,45]. Levosimendan
inhibits the release of reactive oxygen species in polymorphonuclear
leukocytes in vitro and in patients with acute HF and septic shock
[46]. Endothelial function is substantially improved in advanced chronic
HF [47], which might explain the beneﬁcial effects of levosimendan on
coronary blood ﬂow that have been seen in previous haemodynamic
[48,49] and echocardiographic [50,51] studies.
Furthermore, a meta-analysis of randomised controlled studies
showed that the release of troponin after cardiac surgery was lower in
levosimendan-treated patients than in the control groups [52]. In addi-
tion, levosimendan improved right ventricular function in patients with
advanced HF [53]. Due to these effects, hepatic congestion can be im-
proved in patients with acute decompensated HF, according to a sub-
analysis of the SURVIVE study [54].
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The following search strategy was used to ﬁnd previous studies on
repetitive or intermittent use of levosimendan. Medline and Embase
(1990 to 15 October, 2013) were searched via an Ovid interface:
[Levosimendan] AND [repetitive OR intermittent]. The searchwas limit-
ed to English language and human. Twelve references were found, nine
of whichwere considered to be relevant to the subject under discussion
(see Table 1). No relevant Cochrane reviews were identiﬁed at the mo-
ment of the search.
Nanas et al. [55] compared the efﬁcacy and safety of bi-weekly
levosimendan added to daily dobutamine infusion versus daily dobuta-
mine infusions alone in patients who were refractory to an initial 24-h
dobutamine infusion. This prospective trial was open label and the
treatment assignment was not randomised, but instead sequential.
Intermittent levosimendan infusions dramatically increased patient
survival, with 61% vs. 6% of the patients still alive at 45 days.
Levosimendan every 3 weekswas comparedwith placebo by Parissis
et al. [56] In 25 patients with advanced chronic HF, levosimendan pro-
moted signiﬁcant improvements in LVEF, levels of the N-terminal
prohormone of brain natriuretic peptide (NTproBNP) and IL-6, and
end-systolic stress (asmeasured by echocardiography), without increas-
ing myocardial injury, according to troponin T measurements.
Mavrogeni et al. [57] showed signiﬁcant symptom improvement and
increases in left ventricular systolic function, as well as a reduction in
mortality, with intermittent monthly infusions of levosimendan over
6 months, compared to standard care. LVEF improved signiﬁcantly, as
did end-diastolic and end-systolic volumes. On the other hand, in the
trial by Berger et al. [58], patients with intolerance to the appropriate
beta-blocker therapy beneﬁted to a greater extent from continuous treat-
ment with prostaglandin E1 than from 24-h levosimendan at 4-weekly
intervals, with regard to up-titration of beta-blockers. The composite
end-point of HF worsening, death, urgent heart transplantation, and/or
implantation of left ventricular assist device was also in favour of prosta-
glandin E1 (11% vs. 31% for levosimendan, p = 0.04). In this study by
Berger et al., [58] two patients per group died during the 12-week treat-
ment (5% vs. 6% for levosimendan and comparator, respectively; n.s.)
and at the end of the 1-year follow-up, 6 patients had died in the
levosimendan group versus 7 in the control group (n.s.).
Papadopoulou et al. [59] demonstrated improvements in both objec-
tive echocardiographic measurements and subjective quality of life
measures with 24-h levosimendan, although they did not have a com-
parator group. Kleber et al. [38] assessed repetitive levosimendan treat-
ment in 28 patients with pulmonary hypertension, with most of them
suffering from systolic HF. Compared to placebo, levosimendan reduced
pulmonary vascular resistance and mean pulmonary artery pressure to
a signiﬁcantly greater extent. During the study, one patient died in the
placebo group and none in the levosimendan group.
In the randomised study by Bonios et al. [60], 63 patients with de-
compensated end-stage HF refractory to standard therapy were
randomised to levosimendan, dobutamine, or levosimendan plus dobu-
tamine after stabilisation and successful weaning from initial inotropic
agents. A highly signiﬁcant beneﬁt was observed for the event-free
survival with levosimendan only, while patients who received the
combination fared worst. At 6 months, the mortality rate was 19% in
the levosimendan arm, 38% in the dobutamine arm (p = 0.037 vs.
levosimendan), and 48% in the combination arm (p = 0.009 vs.
levosimendan).
Monthly levosimendan was compared with furosemide by Malfatto
et al. [61] The levosimendan therapy resulted in signiﬁcant reductions
in New York Heart Association (NYHA) classes and improvements in
echocardiographic parameters and BNP levels. In the levosimendan
group, 1-year mortality tended to be lower than in the control group
(18.2% vs. 36.4%, respectively).
The prospective, multicentre, randomised, placebo-controlled,
double-blind, two-armed, parallel-group LevoRep Studywas the largest
363M.S. Nieminen et al. / International Journal of Cardiology 174 (2014) 360–367trial on repetitive, ambulatory administration of inotropes for end-stage
HF [62,63]. Overall, 120 patients with chronic stable HF, as NYHA III/IV
for N3 months, LVEF≤35%, and 6-min-walk distance b350 m, received
individually optimised neurohormonal background therapy and
were randomised to placebo or levosimendan 0.2 μg/kg/min for 6 h at
2-week intervals for a total of 4 infusions. The combined primary end-
point was for improvement in functional capacity of ≥20% according
to the 6-min-walk test, plus improvement in patient quality of life of
≥15% as assessed by the Kansas City Cardiomyopathy Questionnaire
score. At the end of the 24-week follow-up, the primary endpoint was
not reached, despite a non-signiﬁcant positive trend in favour of
levosimendan. However, the study met its secondary end-points: com-
pared to placebo, ambulatory levosimendan was safe and improved
event-free survival (deﬁned as freedom from death of all causes, heart
transplant/ventricular assist device [VAD] implantation or acute HF)
by 50% in the long term (24 weeks). This favourable effect was accom-
panied byNT-proBNP decreases of≤30% in nearly half of the patients at
8 weeks. Across both of these arms, similar percentages of patients ex-
perienced adverse events. The potential reasons formissing the primary
endpoint in this LevoRep study include under-dosing of the study drug
(see comparison of cumulative doses in various studies in Table 1),
insufﬁcient size of the study population, and favourable effects in the
placebo arm due to the high quality of care. Also, the combined end-
point might have been too ambitious. Although caution should be
exercised in interpreting favourable effects in secondary outcomes,
the reduction in event-free survival is promising.
Finally, it is worth mentioning that Parle et al. [64] reported data on
repeated infusions of levosimendan in patients with decompensated
HF, collected in a single-centre, prospective, non-randomised study.
Here, the 44 patients received levosimendan from 2 to 26 times, with
a mean dosing interval of 66.2 ± 12 days. Levosimendan was consid-
ered to have been well tolerated and to have improved functional
capacity.
A meta-analysis on the effects on mortality of repetitive use of
levosimendan versus any comparator in patients with advanced HF
was performed by selecting studies that had reported mortality at the
end of the follow-up period (7 of the 9 studies listed in Table 1). The
data on outcome extracted from those papers were analysed with
RevMan 5.2 (freeware available from The Cochrane Collaboration)
[65]. The analysis showed a signiﬁcant reduction in mortality, with a
risk ratio of 0.47 [0.32–0.70] (p = 0.0002) and a low heterogeneity
(Fig. 1).
During the revision of the present manuscript, a new meta-analysis
on the effects of levosimendan on mid-term survival in chronic heart
failure patientswas published [66] inwhich levosimendanwas associat-
ed with a signiﬁcant reduction in mortality at the longest follow-up
available [32 of 168 (19%) in the levosimendan group 46 of 133 (35%)
in the control arm, RR = 0.55 (95% CI 0.37–0.84), p for effect = 0.005,
p for heterogeneity = 0.3, I2 = 23.4%, NNT = 6, with 5 studies
included].
In an overall analysis, it appears that, the existing literature on the
repetitive use of levosimendan is not uniform. The studies vary in
their control arm (placebo, diuretics, dobutamine), and for the dose
and the interval of levosimendan administration, the designs, and the
selection of primary and secondary outcome measures. It appears also,
however, that a general positive trend in favour of the repetitive use
of levosimendan is present. For this reason we performed our meta-
analysis of the mortality data. Since the meta-analysis is based on few
mortality events (24 in the levosimendan group vs. 49 in the control
group) any conclusion based on it should only be taken as hypothesis
generating.
On the other hand, also in the meta-analysis by Silvetti et al. [66]the
authors show a general homogeneity in themortality results among the
studies, and a low risk of bias (as shown by the funnel plot). Moreover,
their result is still signiﬁcantly in favour of levosimendan although they
did not introduce in their calculation the data of Nanas et al. [55], asequential clinical study which, in our own calculation, contributes for
44% of the events.
5. On-going trials
At present, intermittent dosing of levosimendan is being assessed in
a double-blind fashion in the LION-HEART, LAICA and ELEVATE studies
(Table 2).
The LION-HEART trial is evaluating the safety and efﬁcacy of repeti-
tive 6-h doses of levosimendan every 2 weeks, as compared to placebo.
The primary endpoint is the change in NT-proBNP levels between base-
line and end of treatment, 12 weeks later.
The LAICA study is assessing the effects of intermittent repeated
levosimendan every 30 days (for 1 year) on combined overall mortality
rate and hospital admission rate for acute cardiac decompensation or HF
worsening [67]. A sub-study is evaluating the treatment effects on renal
function, while another sub-study is focused on the cost-effectiveness.
The ELEVATE study aims to investigate the effects of levosimendan
versus diuretics on hospitalisation-free survival, with the treatment ap-
plied in patients with early signs of decompensation for impending
destabilisation.
6. Recommendations on intermittent levosimendan therapy
Repetitive use of levosimendan as referred to here is deﬁned as
“scheduled” repeated or intermittent administration. Based on the re-
sults of the studies described above, it appears reasonable to provide
recommendations for such use of levosimendan in selected patients, at
certain doses, and with due monitoring, with the aim of improving he-
modynamic stability, reducing clinical markers and symptoms, and pos-
sibly mortality and hospitalisation for acute deterioration of cardiac
function.
6.1. Identiﬁcation of the Advanced Heart Failure population
It can be challenging to deﬁne advanced or end-stage HF due to the
natural ﬂuctuations in the later stages of this disease. However, some
useful criteria have been provided by various boards. In a position state-
ment published in 2007, the Study Group on Advanced Heart Failure of
the Heart Failure Association of the ESC indicated six criteria for the
deﬁnition of advanced chronic HF [68], and these have become widely
accepted (see Table 3).
The study group made a distinction between advanced chronic HF
and end-stage HF: while cardiac dysfunction and symptoms are poten-
tially reversible in advanced chronic HF, in end-stage HF, they are not.
Furthermore, the ESC position paper deﬁnes the criteria for severe cardi-
ac dysfunction. These are applied on the assumption that optimal treat-
ment that includes beta blockers, angiotensin-converting enzyme
inhibitors, diuretics including aldosterone antagonists, and cardiac
resynchronization therapy (CRT), if indicated, has already been initiated,
without any further response.
These clinical criteria for the identiﬁcation of patientswith advanced
HF (Table 3) are also included in the 2013 American College of Cardiol-
ogy Foundation/American Heart Association guidelines [69]. These en-
compass factors such as NYHA 3+ to 4 class heart failure, repeated
(≥2) hospitalisation or Emergency Department visits for HF in the
past year, progressive deterioration in renal function, weight loss
without other causes, intolerance to angiotensin-converting enzyme in-
hibitors or beta blockers, frequent systolic blood pressure b90 mm Hg,
and exercise intolerance.
6.2. Indications for repetitive levosimendan use
In the framework of the patient population described in the previous
paragraph, and according to the published studies (Table 1, Fig. 1), the
panel reached a consensus for the deﬁnition of potential indications
Fig. 1.Meta-analysis: reduction in mortality rates using repetitive levosimendan therapy.
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risk setting is as listed in Table 4.
As an example, suitable patients are both those listed for heart trans-
plantation orwaiting for VAD implantation, and thosewith similar char-
acteristics but who are not eligible (palliative). The treatment goals
differ, however, between these two groups. While the preservation of
organ function (e.g., renal and hepatic function) should be achieved as
a bridging measure in patients who are scheduled for transplantation
or VAD implantation, the stabilisation and well-being of the patients,
and their avoidance of re-hospitalisation, represent the most important
goal in the palliative setting. Although this has not been studied specif-
ically, repetitive levosimendan use can potentially contribute to reduc-
tion in the emergency transplantation rate, as well as in the rate of
patients dying on the transplantation list. If circumstances permit, inter-
mittent levosimendan therapymight ideally be conducted on an outpa-
tient basis (as in the LevoRep study [62]).
In clinical follow-up, caution must be taken regarding the possible
adverse effects of levosimendan on systolic blood pressure, and poten-
tially on arrhythmias. Risk assessment should always precede initiation
of therapy. The patients should receive optimal medical background
therapy. Prolonged hypotension should be avoided.
Standard cardiac procedures should not be unduly delayed or
neglected because of the availability of intermittent medical treatment;
i.e. this is not a substitute for VAD, CRT, transplantation, or other inter-
ventions in the treatment of patients with chronic advanced HF. Before
initiating repetitive use of levosimendan, baselineNT-proBNP and echo-
cardiography are helpful.
6.3. Dosing
As patient characteristics and needs vary considerably, as well as
their responses to treatment, we recommend the ﬂexible dosing of
0.05 μg/kg/min to 0.2 μg/kg/min, for 6 h to 24 h, every 2 weeks to
4 weeks. Treatment can be started with low dosing, and can be in-
creased stepwise during the remaining time up to 24 h. Hypotension
and arrhythmias were described as adverse events in the two Phase III
clinical studies SURVIVE [70] and REVIVE [37]. Both of these studies in-
cluded bolus levosimendan dosing and relatively high maintenanceTable 2
Ongoing trials that are assessing intermittent or repetitive levosimendan treatment.
Name of the trial
(acronym, NCT code)
Expected N
(design)
The Intermittent Intravenous Levosimendan in Ambulatory Advanced Chronic
Heart Failure Patients study (LION-HEART, NCT01536132)
69 (1:1 vs
The Randomised, Double-blind, Placebo-controlled, Multicentre Trial
to Study Efﬁcacy, Security, and Long-term Effects of Intermittent Repeated
Levosimendan Administration in Patients with Advanced Heart Failure
(LAICA, NCT00988806)
213 (1:1 v
The Early LEvosimendan Versus Usual Care in Advanced Chronic hearT failurE
(ELEVATE, NCT01290146)
134 (1:1 vinfusion rates. These factors might have predisposed the patients to
these adverse events. Therefore, it is believed that bolus levosimendan
application should only be administered if immediate effects are re-
quired and if systolic blood pressure exceeds 100 mmHg. Furthermore,
the maintenance infusion rate might need to be down-titrated if such
adverse events occur. In the case of intermittent application, the use of
bolus levosimendan is thus not recommended. Hypokalaemia and
hypovolaemia should be avoided before and during treatment.
6.4. Monitoring
For safety purposes, the monitoring of blood pressure, heart rate,
bodyweight, serum sodium and potassium levels, and serum creatinine
levels is recommended when i.v. levosimendan is administered.
In general, a systolic blood pressure of 85mmHg to 100mmHgdoes
not rule out treatment with repetitive use of levosimendan, although
there should be close monitoring according to the patient proﬁle. The
volemic status of the patient must be carefully evaluated when i.v.
levosimendan is administered and, in the case of hypovolemia, ﬂuid
substitution during infusionmight beneeded. In the case ofmore severe
hypotension the dose of levosimendanmight need to be temporarily re-
duced and/or a vasopressor added (e.g. noradrenaline). An intense di-
uresis as a result of levosimendan treatment might be seen in some
patients. The elimination or reduction of the regular diuretic on the
day of treatment should thus be considered, and additional ﬂuid given
as needed.
Kidney function assessment is of interest in patients with known
renal dysfunction and in those on diuretic treatment. While secondary
renal dysfunction does not preclude treatment with repetitive use of
levosimendan (see Yilmaz et al. [71]), caution should be exercised in pa-
tients with intrinsic kidney failure.
Due to the individual nature of the course of chronic advanced HF,
there can be no universal recommendations relating to a glomerular ﬁl-
tration rate (GFR) cut-off with regard to repetitive levosimendan use.
However, a GFR of ~30 mL/min/1.73 m [2] might constitute a certain
safety threshold [72].
If furosemide is administered concurrently, the doses should be ad-
justed. Omitting or reducing the diuretic treatment for the morningDose
(μg × kg−1 × min−1)
Infusion
Length (h)
Treatments
(study duration)
placebo) 0.2 6 Every two weeks
(per 3 months)
s placebo) 0.1 24 Every 15 or 30 days
(per 12 months)
s furosemide) 0.05 or 0.1 24 At early signs of deterioration
(per 12 months)
Table 3
Criteria for the deﬁnition of advanced chronic heart failure indicated by the Study Group
on Advanced Heart Failure of the Heart Failure Association of the European Society of
Cardiology [67].
Deﬁnition of advanced heart failure
Severe symptoms of heart failure (NYHA class III or IV)
Episodes of ﬂuid retention and/or peripheral hypoperfusion
Objective evidence of severe cardiac dysfunction
Severe impairment of functional capacity
History of ≥1 heart failure hospitalisation in the past 6 months
Presence of all of the previous features despite “attempts to optimise” therapy
365M.S. Nieminen et al. / International Journal of Cardiology 174 (2014) 360–367before levosimendan therapy can help to avoid sudden drops in blood
pressure and the ensuing renal complications. Where there is an inten-
tion to deliver therapy in an outpatient setting, we recommend that the
ﬁrst administration(s) of levosimendan are performed in hospital
(ideally day-hospital),withmonitoring of blood pressure andheart rate.
The agenda and intervals of monitoring visits should be determined
according to the individual patient risk assessment.
Other guidance measures for these patients on repetitive
levosimendan therapy include counselling on diet and exercise/daily
activity/rest, as well as quality-of-life evaluation. Ideally, trained HF
nurses can perform these tasks in global HF management programme
settings, according to standardised protocols. The application of the in-
terval of 2–4 weeks should be triggered by the increasing symptoms of
the patient.
7. Potential future studies/registries
There is deﬁnitely a need for more solid data on hospitalisation and
mortality rates associated with repetitive use of levosimendan.
The three studies that are on-going (see above) should certainly
shed some light on the effects of such treatment on long-term clinical
outcome. When these data join the data pool, the present open ques-
tions might be answered, based on the substantial patient numbers.
Moreover, if the interim results of LAICA are promising, expansion of
the study to other centres in Europe is conceivable. In turn, the extended
data pool might give rise to distinct questions that can be addressed in a
prospective manner. A parallel approach might be analyses on the basis
of registries, such as the Swedish Heart Failure Registry [73].
8. Conclusions
Overall, patients with chronic advanced HF constitute a relatively
small, but important, population that faces substantial morbidity with
frequent hospitalisation and high mortality. Substantial treatment
costs contribute to the great burden caused by chronic advanced HF. A
subset of these patients will continue to progress and develop more se-
vere symptoms despite optimal therapy. For this group, repetitive
levosimendan therapy might represent a comparatively safe and effec-
tive treatment option.
Levosimendan has now been in extensive clinical use for over
10 years. Using levosimendan intermittently is a novel approach that
has raised interest within the medical community. To date, nine studies
that have includedmore than 500 patients have evaluated repetitive useTable 4
High-risk setting deﬁning the patients who could beneﬁt from repetitive use of
levosimendan in chronic advanced HF.
Indication for levosimendan use in advanced heart failure
• Severe systolic dysfunction (LVEF b35%)
• and/or NYHA IIIb–IV and/or INTERMACS levels 4, 5, 6
• and/or Repeated hospitalisation or emergency department visits (≥2 in the past
year)
• All of the above despite optimal treatment for heart failureof levosimendan in patients with chronic advanced HF. Disparities in pa-
tient selection and in study design and follow-up render this comparison
and any ﬁrm conclusions from these trials difﬁcult; nonetheless, beneﬁts
of the repetitive use of levosimendan have been demonstrated.
There is evidence showing improvements in haemodynamics,
symptoms, rehospitalisation rates, and biomarkers. The issue of mortal-
ity, however, remains to be resolved, which will require further studies.
Thus, our suggestions must be taken with caution and in full respect of
the local guidelines. The trials that are ongoing will add valuable infor-
mation to the existing data.
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